Share Twitter LinkedIn Facebook Email Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter"™s syndrome. Read here: https://meetinglibrary.asco.org/record/186876/abstract Advertisement
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023] Other 1 Min Read